Routes of Administration Described in Specifications of 236 Types of Intravenous Injections

doi:10.19803/j.1672-8629.2021.09.16

Abstract

Abstract: Objective To investigate how routes of administration are described in the specifications of intravenous injections in order to provide reference for clinical rational drug use and prevent off-label use of medicines. Methods The routes of administration of 236 types of intravenous injections described in the specifications were statistically analyzed, and the difference in the descriptions of how these intravenous injections were administered was studied. Results The descriptions about routes of administration of eleven of these intravenous injections were non-standard in the specifications (4.7%), and intravenous injection and intravenous infusion were not clearly defined. Conclusion Non-standard descriptions of routes of administration in the specifications of intravenous injections are an urgent issue to be addressed by enterprises and related departments of the National Medical Products Administration.

Key words: intravenous injections, specification, medication, investigation and analysis

CLC Number:

R969.3

LUO Yichong, CAI Liping, PU Yanfang, ZHAO Jinhua. Routes of Administration Described in Specifications of 236 Types of Intravenous Injections[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 872-875.

References

[1] Cui FD.Pharmacy, Version 2.(药剂学)[M]. Beijing: China Medical Science and Technology Press, 2011: 207-209.
[2] National Medical Products Administration. Administrative regulat-ions of dispensatory and labels(药品说明书和标签管理规定)[S]. National Medical Products Administration, 2006.
[3] National Medical Products Administration. Notice on the issuance of Writing Requirements and Guiding Principles for the Format and Content of Prescription Manual of Traditional Chinese Medicine and Natural Medicine(关于印发中药、天然药物处方药说明书格式内容书写要求及撰写指导原则的通知)[S]. National Medical Products Administration, 2006.
[4] National Medical Products Administration.Notice on the issuance of detailed terms for the dispensatory of chemical drugs and biological products(关于印发化学药品和生物制品说明书规范细则的通知)[S]. National Medical Products Administration, 2006.
[5] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China(中华人民共和国药典)[S]. Beijing: China Medical Science and Technology Press, 2020.
[6] Zhang Q, Wu YZ, Fu H, et al.stability study on omeprazole sodium for injection in two different administration methods[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2018,35(11): 1652-1655.
[7] China Health Promotion Foundation, Chinese Pharmacists Association, China National Pharmaceutical Packaging Association, et al. Protect the safety on the tip of the needle-the consensus of experts on Chinese transfusion safety and protection[J] Drug Evaluation(药品评价), 2016, 13(10): 8-17.
[8] Zhang JS, Qi Y, Wang XL, et al.stability study on compatibility of omeprazole solution for injection[J]. China Pharmacist(中国药师), 2007, 10(4): 352-354.
[9] National Medical Products Administration.Adverse reaction information notification(38)Be alert to severe allergic reaction of asarum cerebral injection[DB/OL].(2011-06-10)[2019-11-20]. http://www.nmpa.gov.cn/WS04/CL2155/318854.html .
[10] National Medical Products Administration. Notice of General Office of the National Medical Products Administration on Revising the Dispensatory of Asarum Cerebral Injection[S]. Food and Drug Administration (drug chemical tube), 2014. No. 78.
[11] Wang YL, Investigation and analysis of 40 groups of injection instructions in our hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒)2018, 15(3): 147-151, 168.
[12] Hu X, Zhang YM, Liu X, et al.Investigation and suggestions on the labelling of 75 intravenous antiinfective drugs instructions[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 68-170.
[13] Li MJ, Shi TL, Zhang ZT.An analysis of 170 intravenous drug delivery routes[J]Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2017, 17(10): 1408-1410.

[1]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[2]	BUCHANAN James. Assessment of drug-induced liver injury via nR modified Hy’s law and P_ALT [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
[3]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[4]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[5]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[6]	LUO Qiong, LI Meng, LI Guangyao, HE Yanchun, ZHOU Zushan, SUN Xin, LIU Chenghai. Chinese medical evidence and characteristics of combined medication in 635 cases of rheumatoid arthritis patients with liver injury caused by the application of Tripterygium wilfordii preparations [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 500-504.
[7]	ZHANG Qingxia, ZHOU Liujun, LI Xiaoling, WANG Yuqin. Cefoperazone/sulbactam-related medication errors in the elderly and countermeasures [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 574-578.
[8]	DING Qian, LI Boyu, ZHANG Qingxia. Risks to storage of nitroglycerin after unsealing and ways of prevention [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 326-330.
[9]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[10]	SUN Jing, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, CUI Xiaolan. Effects of Shufeng Jiedu capsules combined with levofloxacin in the treatment of mouse pneumonia infected by multidrug-resistant Pseudomonas aeruginosa [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 52-56.
[11]	ZHANG Qingxia, JIANG Yongxian, LI Gen, YAN Suying, WANG Yuqin. Analysis and prevention of medication errors related to stored pharmaceuticals in National Monitoring Network for Clinical Safety Medication [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1040-1044.
[12]	ZHANG Hongwei, LI Yuanyuan, XIE Yanming, MA Xiaochang, WANG Lianxin, WEI Ruili, SUN Linxi, XU Hongyan, ZHUANG Yan. The drug combination of Danshen Ligustrazine injection in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 851-856.
[13]	WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin. Pareto chart analysis of 705 problematic prescriptions in neurology [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903.
[14]	LI Meiyun, TANG Guangliang, CHEN Zhihong, HE Xin, CHEN Shenjue, LI Xin, LIU Lihua. Analysis of 107 reports of ADR induced by ribavirin [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 770-774.
[15]	WANG Zhonglan, WANG Yu, HAO Lina, HU Lihua, WANG Xiaoling, ZHAO Zhigang. Taking wrong medicines by children and precautions [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 779-781.